Free tool
FAERS Monitor: Iheezo
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 216227 or its brand name (Iheezo, Chloroprocaine Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
108
Serious
4
4% of reports
Hospitalization
0
Death reported
0
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective55
- underdose54
- eye irritation21
- eye pain20
- ocular hyperaemia8
- lacrimation increased7
- ocular discomfort7
- product temperature excursion issue7
- conjunctival hyperaemia6
- off label use5
- vision blurred3
- corneal abrasion2
- eyelid margin crusting2
- hypersensitivity2
- conjunctival haemorrhage1
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2024 | 2 |
| 2025 | 12 |
| 2026 | 94 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,051 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| conjunctival hyperaemiaSignal | 6 | 328.4 | 150.8 | 1,642 |
| corneal abrasion | 2 | 284.6 | 72.0 | 317 |
| product temperature excursion issueSignal | 7 | 265.7 | 129.7 | 1,589 |
| underdoseSignal | 54 | 144.2 | 119.4 | 7,556 |
| eyelid margin crusting | 2 | 134.9 | 34.1 | 149 |
| ocular discomfortSignal | 7 | 121.5 | 59.3 | 720 |
| eye irritationSignal | 21 | 71.1 | 48.4 | 1,385 |
| eye painSignal | 20 | 69.1 | 46.5 | 1,277 |
| conjunctival haemorrhage | 1 | 51.0 | 7.2 | 12 |
| lacrimation increasedSignal | 7 | 45.1 | 22.0 | 260 |
| ocular hyperaemiaSignal | 8 | 32.8 | 16.9 | 217 |
| drug ineffectiveSignal | 55 | 8.1 | 6.8 | 359 |
| vision blurredSignal | 3 | 4.3 | 1.4 | 5 |
| hypersensitivity | 2 | 2.1 | 0.5 | 0 |
| off label use | 5 | 1.1 | 0.5 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.